

THE CITY OF NEW YORK OFFICE OF THE COMPTROLLER BRAD LANDER

July 15, 2024

Brian S. Tyler Chief Executive Officer McKesson Corporation 6555 State Highway 161 Irving, Texas 75039

Dear Mr. Tyler:

As Comptroller of the City of New York, I am the investment adviser to, and the custodian and a trustee of, the New York City Retirement Systems (NYCRS). NYCRS holds approximately 334,000 shares in McKesson Companies, valued at \$190 million (as of 5/31/24).

I am writing to urge McKesson to immediately take the necessary steps for Health Mart to receive certification to dispense the medication mifepristone in states where it is legal. Following pharmacy industry leaders, and competitors, CVS and Walgreens, McKesson has the opportunity to provide access to abortion medication through its Health Mart pharmacies. Making mifepristone available benefits customers and employees and increases sales, while also generating long-term shareholder value.

The McKesson Board of Directors' and management's failure to publicly commit to Health Mart becoming a certified mifepristone dispenser therefore raises significant investor concerns. These concerns include the company's responsiveness to a growing market opportunity, its mitigation of potential reputational risks, and its commitment to maximizing sales and long-term shareholder value.

Medication abortion now accounts for 63% of all abortions in the health care system, as noted in a July 2, 2024, letter from a group of 54 U.S. House members that similarly called on Health Mart to take action to begin dispensing mifepristone as soon as possible. According to Global Markets Insight Inc., the market for abortion drugs was valued at over \$24.4 billion in 2023 and is estimated to grow at 8.2% annually through 2032. According to Global Markets Insight Inc., the market for abortion drugs was valued at over \$24.4 billion in 2023 and is estimated to grow at 8.2% annually through 2032.

Mifepristone's safety is well established. The U.S. Food and Drug Administration thoroughly reviewed the scientific evidence and approved Mifeprex (mifepristone) over 20 years ago, determining its safety and effectiveness.ⁱⁱⁱ

According to an amici curiae brief submitted to the U.S. Supreme Court by 16 of the nation's leading medical organizations representing hundreds of thousands of clinicians nationwide (including the American College of Obstetricians and Gynecologists (ACOG) and the American Medical Association (AMA)), "few drugs have been so extensively studied after their approval by FDA and can boast such a clear and compelling record of safe use." The amici curiae further notes, "Mifepristone has a safety profile comparable to that of ibuprofen, which more than 30 million Americans take in any given day."

Following the recent Supreme Court decision allowing for continued access to mifepristone, the ACOG stated: "[a]ccess to the full spectrum of medical care, including abortion, is essential for people's health, safety, and well-being."

It is incumbent on the Board and management to promptly act to ensure that Health Mart quickly becomes certified and starts dispensing mifepristone without delay. This action aligns with both long-term shareholder interests and women's health care needs.

I thank you in advance for your timely response.

Sincerely,

Brad Lander

New York City Comptroller

Cc: Donald R. Knauss, Independent Chairman

Saralisa C. Brau, Corporate Secretary & Assistant General Counsel

essential#:~:text=Access% 20to% 20the% 20full% 20spectrum,to% 20people% 20without% 20outside% 20interference.

i https://goldman.house.gov/sites/evo-subsites/goldman.house.gov/files/evo-media-document/7.2_MifeLetter_FINAL.pdf

ii https://www.gminsights.com/industry-analysis/abortion-drugs-market/market-size\

iii https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-mifepristone-medical-termination-pregnancy-through-ten-weeks-

gestation#:~:text=The%20FDA%20approved%20Mifeprex%20more,to%2070%20days%20of%20gestation.

https://www.acog.org/-/media/project/acog/acogorg/files/advocacy/amicus-briefs/2024/20240130-danco-laboratories-llc-v-alliance-for-hippocratic-medicine-et-al.pdf

^v https://www.acog.org/-/media/project/acog/acogorg/files/advocacy/amicus-briefs/2024/20240130-danco-laboratories-llc-v-alliance-for-hippocratic-medicine-et-al.pdf

vi https://www.acog.org/advocacy/abortion-is-